Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 1, 1996, Pages 41-48

  Pui Kai, Li ^a   Milano, Shawn ^a   Kluth, Lisa ^a   Rhodes, Michael E ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; ESTRONE SULFATE; SULFATASE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; PLACENTA;

BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; HUMANS; MICROSOMES; MOLECULAR STRUCTURE; PLACENTA; SULFATASES; TYRAMINE;

EID: 0030238263     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00093-3     Document Type: Article

References (23)

1. 1. Noel C. T., Reed M. J., Jacobs H. S. and James V. H. T.: The plasma concentration of oestrone sulphate in postmenopausal women: lack of diurnal variation, effect of ovariectomy, age and weight. J. Steroid Biochem. 14 (1981) 1101-1105.
2. 2. Samojilik E., Santen R. J. and Worgul T. J.: Plasma estrone sulfate: assessment of reduced estrogen production during treatment of metastatic breast cancer. Steroids 39 (1982) 497-503.
3. 3. Pasqualini J. R., Chetrite G., Nguyen B.-L., Maloche C., Delalonde L., Talbi M., Feinstein M.-C., Blacker C., Botella J. Paris J.: Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid Biochem. Molec. Biol. 53 (1995) 407-412.
4. 4. Santner S. J., Feil P. D. and Santen R. J.: In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance vs the aromatase pathway. J. Clin. Endocr. Metab. 59 (1984) 29-33.
5. 5. Santen R. J., Leszczynski D., Tilson-Mallet N., Feil P. D., Wright C., Manni A. and Santner S. J.: Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Annu. N.Y. Acad. Sci. 464 (1986) 126-137.
6. 6. Evans T. R. J., Rowlands M. G., Jarman M. and Coombes R. C.: Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. J. Steroid Biochem. Molec. Biol. 39 (1991) 493-499.
7. 7. Duncan L., Puroit A., Howarth N. M., Potter B. V. L. and Reed M. J.: Inhibition of estrone sulfate activity by estrone-3-methylthiophosphonate. Cancer Res. 53 (1993) 298-303.
8. 8. Howarth N. M., Cooper G., Purohit A., Duncan L., Reed M. J. and Potter B. V. L.: Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone-3-methylthiophosphonate, a potent inhibitor of estrone sulfatase. Bioorg. Med. Chem. Lett. 3 (1993) 313-318.
9. 9. Howarth N. M., Purohit A., Reed M. J. and Potter B. V. L.: Estrone sulfamates: potent inibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37 (1994) 219-221.
10. 10. Li P. K., Pillai R., Young B. L., Bender W., Martino D. M. Lin F. T.: Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids 58 (1993) 106-111.
11. 11. Dibbelt L., Li P. K., Pillai R. and Knuppen R.: Inhibition of human placental sterylsulfatase by synthetic analogs of estrone sulfate. J. Steroid Biochem. Molec. Biol. 52 3 (1995) 281-286.
12. 12. Li P. K., Pillai R. and Dibbelt L.: Estrone sulfate analogs as estrone sulfatase inhibitors. Steroids 60 (1995) 299-306.
13. 13. Purohit A., Williams G. J., Howarth N. M., Potter B. V. L. Reed M. J.: Inactivation of steroid sulfatase by an active-site directed inhibitor, estrone-3-O-sulphamate. Biochemistry 34 (1995) 11508-11514.
14. 14. Purohit A., Williams G. J., Roberts C. J., Potter B. V. L. and Reed M. J.: In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by estrone-3-sulphamate. Int. J. Cancer 63 (1995) 106-111.
15. 15. Elger W., Schwarz S., Hedden A., Reddersen G. and Schneider B.: Sulfamates of various estrogens - prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Molec. Biol 55 (1995) 396-403.
16. 16. Appel R. and Berger G.: Uber das Hydrazidosulfamid. (On hydrazidosulfamide). Chem. Ber. 91 (1958) 1339.
17. 17. Ryan K. J.: Biological aromatization of steroids. J. Biol Chem. 234 (1959) 268-272.
18. 18. Lowry O. H., Rosebrough M. J., Farr A. L. and Randall R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275.
19. 19. Vignon F., Terqui M., Westley B., Derocq D. and Rochefort H.: Effects of plasma oestrogen sulphates in mammary cancer cells. Endocrinology 106 (1980) 1079-1086.
20. 20. Pasqualini J., Gelly C., Nguyen B. L. and Vella C.: Importance of oestrogen sulphates in breast cancer. J. Steroid Biochem. 34 (1989) 155-163.
21. 21. Purohit A., Williams G. J., Howarth N. M., Potter B. V. L. Reed M. J.: Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulphamate. Biochemistry 34 (1995) 11508-11514.
22. 22. Dibbelt L. and Kuss E.: Human placental sterylsulfatase. Interaction of the isolated enzyme with substrates, products, transition-state analogues, amino-acid modifiers and anion transport inhibitors. Biol. Chem. Hoppe-Seyler 372 (1991) 173-185.
23. 23. Birnbock H. and von Angerer E.: Sulfate derivatives of 2-phenylindoles as novel steroid sulfatase inhibitors. Biochem. Pharmacol. 39 (1990) 1709-1713.